Koshinski Asset Management Inc. Buys 1,215 Shares of Laboratory Co. of America Holdings (NYSE:LH)

Koshinski Asset Management Inc. lifted its position in Laboratory Co. of America Holdings (NYSE:LH) by 23.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,340 shares of the medical research company’s stock after purchasing an additional 1,215 shares during the quarter. Koshinski Asset Management Inc.’s holdings in Laboratory Co. of America were worth $1,441,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the company. Neuberger Berman Group LLC raised its position in shares of Laboratory Co. of America by 0.6% during the 4th quarter. Neuberger Berman Group LLC now owns 7,834 shares of the medical research company’s stock valued at $1,845,000 after buying an additional 48 shares in the last quarter. Guardian Wealth Management Inc. increased its stake in Laboratory Co. of America by 1.0% during the first quarter. Guardian Wealth Management Inc. now owns 5,379 shares of the medical research company’s stock worth $1,418,000 after acquiring an additional 52 shares during the last quarter. Caprock Group LLC raised its position in Laboratory Co. of America by 1.8% during the fourth quarter. Caprock Group LLC now owns 3,084 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 56 shares during the period. UMB Bank n.a. lifted its stake in shares of Laboratory Co. of America by 22.1% in the 3rd quarter. UMB Bank n.a. now owns 315 shares of the medical research company’s stock valued at $63,000 after purchasing an additional 57 shares during the last quarter. Finally, Arjuna Capital boosted its holdings in shares of Laboratory Co. of America by 3.2% in the 3rd quarter. Arjuna Capital now owns 1,819 shares of the medical research company’s stock worth $366,000 after purchasing an additional 57 shares during the period. 95.94% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on LH shares. Evercore ISI assumed coverage on Laboratory Co. of America in a report on Friday, February 9th. They set an “in-line” rating and a $240.00 price target on the stock. TheStreet lowered shares of Laboratory Co. of America from a “b-” rating to a “c+” rating in a report on Thursday, February 15th. Argus upgraded shares of Laboratory Co. of America from a “hold” rating to a “buy” rating and set a $250.00 price target on the stock in a report on Monday, March 25th. SVB Leerink started coverage on shares of Laboratory Co. of America in a research note on Monday, February 26th. They issued an “outperform” rating and a $260.00 price objective for the company. Finally, Leerink Partnrs restated an “outperform” rating on shares of Laboratory Co. of America in a research report on Monday, February 26th. Four investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $243.50.

Laboratory Co. of America Stock Down 0.4 %

Shares of Laboratory Co. of America stock traded down $0.77 during trading on Friday, hitting $205.73. 717,036 shares of the stock traded hands, compared to its average volume of 694,768. Laboratory Co. of America Holdings has a 52-week low of $174.20 and a 52-week high of $234.09. The stock’s fifty day simple moving average is $215.83 and its 200 day simple moving average is $214.65. The firm has a market cap of $17.31 billion, a P/E ratio of 44.05, a price-to-earnings-growth ratio of 1.55 and a beta of 1.01. The company has a current ratio of 1.17, a quick ratio of 1.02 and a debt-to-equity ratio of 0.52.

Laboratory Co. of America (NYSE:LH) last posted its earnings results on Thursday, February 15th. The medical research company reported $3.30 EPS for the quarter, beating analysts’ consensus estimates of $3.29 by $0.01. Laboratory Co. of America had a net margin of 3.24% and a return on equity of 13.99%. The business had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.02 billion. During the same quarter last year, the firm posted $4.14 EPS. The company’s revenue for the quarter was down 17.5% on a year-over-year basis. On average, equities analysts predict that Laboratory Co. of America Holdings will post 14.84 earnings per share for the current fiscal year.

Laboratory Co. of America Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 12th. Shareholders of record on Tuesday, May 28th will be given a dividend of $0.72 per share. The ex-dividend date is Friday, May 24th. This represents a $2.88 annualized dividend and a yield of 1.40%. Laboratory Co. of America’s dividend payout ratio (DPR) is presently 61.67%.

Insider Buying and Selling at Laboratory Co. of America

In other Laboratory Co. of America news, EVP Der Vaart Sandra D. Van sold 259 shares of the business’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $222.06, for a total value of $57,513.54. Following the completion of the transaction, the executive vice president now directly owns 7,637 shares in the company, valued at $1,695,872.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Laboratory Co. of America news, EVP Der Vaart Sandra D. Van sold 259 shares of Laboratory Co. of America stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $222.06, for a total value of $57,513.54. Following the transaction, the executive vice president now directly owns 7,637 shares of the company’s stock, valued at $1,695,872.22. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Der Vaart Sandra D. Van sold 237 shares of the stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $226.45, for a total value of $53,668.65. Following the sale, the executive vice president now owns 7,637 shares of the company’s stock, valued at approximately $1,729,398.65. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 54,305 shares of company stock valued at $11,761,059. 0.65% of the stock is currently owned by corporate insiders.

Laboratory Co. of America Profile

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS).